An Ruopeng, Wang Peizhong Peter
Department of Kinesiology and Community Health, College of Applied Health Sciences, University of Illinois at Urbana-Champaign, Champaign, IL, USA.
Faculty of Medicine, Memorial University of Newfoundland, St. John's, NL, Canada.
Vasc Health Risk Manag. 2017 Jan 20;13:15-21. doi: 10.2147/VHRM.S123631. eCollection 2017.
In this study, we examined the length of stay, hospitalization cost, and risk of in-hospital mortality among US adult inpatients with immune thrombocytopenic purpura (ITP).
We analyzed nationally representative data obtained from Nationwide/National Inpatient Sample database of discharges from 2006 to 2012.
In the US, there were an estimated 296,870 (95% confidence interval [CI]: 284,831-308,909) patient discharges recorded for ITP from 2006 to 2012, during which ITP-related hospitalizations had increased steadily by nearly 30%. The average length of stay for an ITP-related hospitalization was found to be 6.02 days (95% CI: 5.93-6.10), which is 28% higher than that of the overall US discharge population (4.70 days, 95% CI: 4.66-4.74). The average cost of ITP-related hospitalizations was found to be US$16,594 (95% CI: US$16,257-US$16,931), which is 48% higher than that of the overall US discharge population (US$11,200; 95% CI: US$11,033-US$11,368). Gender- and age-adjusted mortality risk in inpatients with ITP was 22% (95% CI: 19%-24%) higher than that of the overall US discharge population. Across diagnosis related groups, length of stay for ITP-related hospitalizations was longest for septicemia (7.97 days, 95% CI: 7.55-8.39) and splenectomy (7.40 days, 95% CI: 6.94-7.86). Splenectomy (US$25,262; 95% CI: US$24,044-US$26,481) and septicemia (US$18,430; 95% CI: US$17,353-US$19,507) were associated with the highest cost of hospitalization. The prevalence of mortality in ITP-related hospitalizations was highest for septicemia (11.11%, 95% CI: 9.60%-12.63%) and intracranial hemorrhage (9.71%, 95% CI: 7.65%-11.77%).
Inpatients with ITP had longer hospital stay, bore higher costs, and faced greater risk of mortality than the overall US discharge population.
在本研究中，我们调查了美国成年免疫性血小板减少症（ITP）住院患者的住院时间、住院费用和院内死亡风险。
我们分析了从2006年至2012年全国住院患者样本数据库中获得的具有全国代表性的数据。
在美国，2006年至2012年期间记录的ITP患者出院人数估计为296,870例（95%置信区间[CI]：284,831 - 308,909），在此期间与ITP相关的住院人数稳步增加了近30%。发现与ITP相关住院的平均住院时间为6.02天（95%CI：5.93 - 6.10），比美国总体出院人群的平均住院时间（4.70天，95%CI：4.66 - 4.74）高出28%。与ITP相关住院的平均费用为16,594美元（95%CI：16,257美元 - 16,931美元），比美国总体出院人群的平均费用（11,200美元；95%CI：11,033美元 - 11,368美元）高出48%。ITP住院患者经性别和年龄调整后的死亡风险比美国总体出院人群高22%（95%CI：19% - 24%）。在各个诊断相关组中，与ITP相关住院的住院时间在败血症（7.97天，95%CI：7.55 - 8.39）和脾切除术（7.40天，95%CI：6.94 - 7.86）时最长。脾切除术（25,262美元；95%CI：24,044美元 - 26,481美元）和败血症（18,430美元；95%CI：17,353美元 - 19,507美元）与最高住院费用相关。与ITP相关住院的死亡率在败血症（11.11%，95%CI：9.60% - 12.63%）和颅内出血（9.71%，95%CI：7.65% - 11.77%）时最高。
与美国总体出院人群相比，ITP住院患者住院时间更长、费用更高且面临更大的死亡风险。
